Subcutaneous Self-Administration Markets to 2022
|出版商||Greystone Research Associates||商品編碼||320682|
Subcutaneous Self-Administration Markets to 2022: Drugs, Devices, Therapeutics, Markets and Forecasts is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.
The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the therapeutics, markets, participants and commercial opportunities for drugs and combination products designed to be self-administered subcutaneously. Provider organization business managers, healthcare administrators and investors will also benefit from this study.
Market and Product Evolution in the Injectable Drug Sector
As healthcare markets continue to evolve, drug developers and their supply chain partners are attempting to keep pace by addressing economic, market and therapeutic factors that increasingly revolve around how, when and where drugs are administered. This evolution is being driven by new and exciting options for patient care in the form of powerful drug therapies for treating diseases with improved outcomes and for treating diseases for which an effective treatment did not previously exist. Beyond oncology - where therapeutics continue to be supplied for administration via infusion - the majority of new non-oral drugs are being formulated for subcutaneous injection. Many of these drugs are indicated for chronic conditions, which because of the continuous need for dosing over time benefit significantly when patients can self-administer their medication. This report examines in detail the drugs, devices, therapeutics and markets that are set to change substantially over the remainder of the decade.